无症状Pembrolizumab相关性高甘油三酯血症
Asymptomatic Pembrolizumab-Associated Hypertriglyceridemia.
摘要(中文译文)
帕博利珠单抗是一种广泛用于实体瘤和血液系统恶性肿瘤治疗的免疫检查点抑制剂，但与免疫相关不良事件相关。虽然已有关于帕博利珠单抗相关症状性高甘油三酯血症伴胰腺炎管理的描述，但缺乏对帕博利珠单抗相关无症状性高甘油三酯血症治疗的指导。在此，我们报告一例在接受九剂帕博利珠单抗治疗后出现的罕见不良事件——帕博利珠单抗相关无症状性高甘油三酯血症。患者的血脂面板显示4级高甘油三酯血症和高胆固醇血症。治疗暂停，患者接受降脂治疗并有所改善。再次挑战后，4级升高再次出现，但仍保持无症状。本病例突出了一种罕见的免疫相关不良事件——无症状性高甘油三酯血症，强调了即使对无症状病例也应常规监测帕博利珠单抗不良事件的重要性。
Abstract
Pembrolizumab is an immune checkpoint inhibitor that is widely used in the treatment of solid and hematological malignancies but is associated with immune-related adverse events. While the management of pembrolizumab-associated symptomatic hypertriglyceridemia associated with pancreatitis has been described, there is a lack of guidance for the treatment of pembrolizumab-associated asymptomatic hypertriglyceridemia. Here, we report a rare adverse event of pembrolizumab-associated asymptomatic hypertriglyceridemia after nine doses of pembrolizumab. The patient's lipid panel revealed grade 4 hypertriglyceridemia and hypercholesterolemia. Treatment was held, and the patient was treated with lipid-lowering therapies with improvement. Upon re-challenge, the grade 4 elevations returned while remaining asymptomatic. This case highlights a rare immune-related adverse event of asymptomatic hypertriglyceridemia. It underlines the importance of routine monitoring for adverse events with pembrolizumab, even in asymptomatic cases.
如何引用
AMA
Lauren S Yeager, Ralph G Zinner, Zhonglin Hao. Asymptomatic Pembrolizumab-Associated Hypertriglyceridemia.. Cureus. 2026; doi:10.7759/cureus.110286.
APA
Lauren S Yeager, Ralph G Zinner, Zhonglin Hao (2026). Asymptomatic Pembrolizumab-Associated Hypertriglyceridemia.. Cureus. https://doi.org/10.7759/cureus.110286
GB/T 7714
Lauren S Yeager, Ralph G Zinner, Zhonglin Hao. Asymptomatic Pembrolizumab-Associated Hypertriglyceridemia.[J]. Cureus, 2026 doi:10.7759/cureus.110286.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出